Trial Profile
The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Ursodeoxycholic acid (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 21 Apr 2011 New trial record